{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:23:36Z","timestamp":1793381016682,"version":"4.5.0"},"reference-count":78,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors have revolutionized cancer treatment by targeting the cytotoxic T lymphocyte antigen-4 and programmed death-1\/ligand-1. Although immune checkpoint inhibitors show promising therapeutic efficacy, they often cause immune-related adverse events. Immune-related adverse events differ from the side effects of conventional chemotherapy and require vigilant monitoring. These events predominantly affect organs, such as the colon, liver, lungs, pituitary gland, thyroid and skin, with rare cases affecting the heart, nervous system and other tissues. As immune-related adverse events result from immune activation, indicating the reinvigoration of exhausted immune cells that attack both tumors and normal tissues, it is theoretically possible that immune-related adverse events may signal a better response to immune checkpoint inhibitor therapy. Recent retrospective studies have explored the link between immune-related adverse event development and clinical efficacy; however, the predictive value of immune-related adverse events in the immune checkpoint inhibitor response remains unclear. Additionally, studies have focused on immune-related adverse events, timing of onset and immunosuppressive treatments. This review focuses on pivotal studies of the association between immune-related adverse events and outcomes in patients treated with immune checkpoint inhibitors.<\/jats:p>","DOI":"10.1093\/jjco\/hyae067","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T08:24:01Z","timestamp":1715243041000},"page":"949-958","source":"Crossref","is-referenced-by-count":45,"title":["The correlation between immune-related adverse events and efficacy of immune checkpoint inhibitors"],"prefix":"10.1093","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1345-5608","authenticated-orcid":false,"given":"Taito","family":"Fukushima","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Kanagawa Cancer Center , Yokohama , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2535-6586","authenticated-orcid":false,"given":"Satoshi","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kanagawa Cancer Center , Yokohama , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Ueno","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kanagawa Cancer Center , Yokohama , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,20]]},"reference":[{"key":"2024090511564960100_ref1","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"key":"2024090511564960100_ref2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cell.2018.09.035","article-title":"A paradigm shift in cancer immunotherapy: from enhancement to normalization","volume":"175","author":"Sanmamed","year":"2018","journal-title":"Cell"},{"key":"2024090511564960100_ref3","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"2024090511564960100_ref4","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"2024090511564960100_ref5","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.bulcan.2018.07.005","article-title":"Physiopathological mechanisms of immune-related adverse events induced by anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies in cancer treatment","volume":"105","author":"Passat","year":"2018","journal-title":"Bull Cancer"},{"key":"2024090511564960100_ref6","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"key":"2024090511564960100_ref7","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"2024090511564960100_ref8","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"2024090511564960100_ref9","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/jamaoncol.2019.0402","article-title":"Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer","volume":"5","author":"Berner","year":"2019","journal-title":"JAMA Oncol"},{"key":"2024090511564960100_ref10","doi-asserted-by":"crossref","first-page":"684","DOI":"10.18632\/oncotarget.323","article-title":"New perspectives on the role of vitiligo in immune responses to melanoma","volume":"2","author":"Byrne","year":"2011","journal-title":"Oncotarget"},{"key":"2024090511564960100_ref11","doi-asserted-by":"crossref","first-page":"11919","DOI":"10.1073\/pnas.1611421113","article-title":"Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities","volume":"113","author":"Subudhi","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024090511564960100_ref12","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41591-021-01623-z","article-title":"T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma","volume":"28","author":"Lozano","year":"2022","journal-title":"Nat Med"},{"key":"2024090511564960100_ref13","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jaad.2019.08.045","article-title":"BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors","volume":"82","author":"Hasan Ali","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2024090511564960100_ref14","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/annrheumdis-2018-213777","article-title":"Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1","volume":"78","author":"Mammen","year":"2019","journal-title":"Ann Rheumat Dis"},{"key":"2024090511564960100_ref15","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"key":"2024090511564960100_ref16","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1016\/j.ajpath.2016.08.020","article-title":"Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series","volume":"186","author":"Caturegli","year":"2016","journal-title":"Am J Pathol"},{"key":"2024090511564960100_ref17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40425-015-0081-1","article-title":"Baseline circulating IL-17 predicts toxicity while TGF-\u03b21 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma","volume":"3","author":"Tarhini","year":"2015","journal-title":"J Immunother Cancer"},{"key":"2024090511564960100_ref18","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/s41591-021-01406-6","article-title":"Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade","volume":"27","author":"Andrews","year":"2021","journal-title":"Nat Med"},{"key":"2024090511564960100_ref19","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.jtho.2017.08.022","article-title":"Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with nivolumab: a prospective cohort study","volume":"12","author":"Teraoka","year":"2017","journal-title":"J Thoracic Oncol"},{"key":"2024090511564960100_ref20","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"key":"2024090511564960100_ref21","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00432-018-2805-3","article-title":"Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis","volume":"145","author":"Ricciuti","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"2024090511564960100_ref22","doi-asserted-by":"crossref","first-page":"e893","DOI":"10.1016\/j.cllc.2018.08.008","article-title":"Incidence, risk factors, and effect on survival of immune-related adverse events in patients with non-small-cell lung cancer","volume":"19","author":"Owen","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"2024090511564960100_ref23","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.cllc.2018.10.002","article-title":"Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer","volume":"20","author":"Grangeon","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"2024090511564960100_ref24","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.cllc.2019.02.006","article-title":"Correlations between the immune-related adverse events spectrum and efficacy of anti-PD1 immunotherapy in NSCLC patients","volume":"20","author":"Cortellini","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"2024090511564960100_ref25","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1001\/jamaoncol.2020.5012","article-title":"Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell lung cancer","volume":"6","author":"Shankar","year":"2020","journal-title":"JAMA Oncol"},{"key":"2024090511564960100_ref26","doi-asserted-by":"crossref","first-page":"2017162","DOI":"10.1080\/2162402X.2021.2017162","article-title":"Association between immune-related adverse event timing and treatment outcomes","volume":"11","author":"Hsiehchen","year":"2022","journal-title":"Oncoimmunology"},{"key":"2024090511564960100_ref27","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/jamaoncol.2022.7711","article-title":"Association of immune-related adverse events with efficacy of atezolizumab in patients with non-small cell lung cancer: pooled analyses of the phase 3 IMpower130, IMpower132, and IMpower150 randomized clinical trials","volume":"9","author":"Socinski","year":"2023","journal-title":"JAMA Oncol"},{"key":"2024090511564960100_ref28","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol"},{"key":"2024090511564960100_ref29","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jtho.2020.11.025","article-title":"Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 IMpower132 trial","volume":"16","author":"Nishio","year":"2021","journal-title":"J Thoracic Oncol"},{"key":"2024090511564960100_ref30","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"2024090511564960100_ref31","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1158\/1078-0432.CCR-07-0187","article-title":"Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade","volume":"13","author":"Downey","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2024090511564960100_ref32","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial Sloan Kettering Cancer Center","volume":"33","author":"Horvat","year":"2015","journal-title":"J Clin Oncol"},{"key":"2024090511564960100_ref33","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"key":"2024090511564960100_ref34","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2024090511564960100_ref35","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00432-018-2819-x","article-title":"Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma","volume":"145","author":"Indini","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"2024090511564960100_ref36","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/CJI.0000000000000271","article-title":"Association between pembrolizumab-related adverse events and treatment outcome in advanced melanoma: results from the Dutch expanded access program","volume":"42","author":"Bisschop","year":"2019","journal-title":"J Immunother"},{"key":"2024090511564960100_ref37","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1001\/jamaoncol.2019.5570","article-title":"Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial","volume":"6","author":"Eggermont","year":"2020","journal-title":"JAMA Oncol"},{"key":"2024090511564960100_ref38","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.794099","article-title":"Correlation between immune-related adverse events and prognosis in hepatocellular carcinoma patients treated with immune checkpoint inhibitors","volume":"12","author":"Xu","year":"2021","journal-title":"Front Immunol"},{"key":"2024090511564960100_ref39","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/ijc.33609","article-title":"Immune-related adverse events predict responses to PD-1 blockade immunotherapy in hepatocellular carcinoma","volume":"149","author":"Lu","year":"2021","journal-title":"Int J Cancer"},{"key":"2024090511564960100_ref40","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000518619","article-title":"Impact of immune-related adverse events on efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma","volume":"11","author":"Ng","year":"2022","journal-title":"Liver Cancer"},{"key":"2024090511564960100_ref41","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1093\/oncolo\/oyad090","article-title":"Association between immune-related adverse events and survival in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab","volume":"28","author":"Fukushima","year":"2023","journal-title":"Oncologist"},{"key":"2024090511564960100_ref42","doi-asserted-by":"crossref","first-page":"689","DOI":"10.4251\/wjgo.v15.i4.689","article-title":"Correlation between immune-related adverse events and long-term outcomes in pembrolizumab-treated patients with unresectable hepatocellular carcinoma: a retrospective study","volume":"15","author":"Zhou","year":"2023","journal-title":"World J Gastrointest Oncol"},{"key":"2024090511564960100_ref43","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s40425-019-0579-z","article-title":"Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program","volume":"7","author":"Verzoni","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2024090511564960100_ref44","doi-asserted-by":"crossref","first-page":"355.e21","DOI":"10.1016\/j.urolonc.2019.03.003","article-title":"Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab","volume":"37","author":"Ishihara","year":"2019","journal-title":"Urol Oncol"},{"key":"2024090511564960100_ref45","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s10147-023-02406-x","article-title":"Association between immune-related adverse events and survival in patients with renal cell carcinoma treated with nivolumab plus ipilimumab: immortal time bias-corrected analysis","volume":"28","author":"Washino","year":"2023","journal-title":"Int J Clin Oncol"},{"key":"2024090511564960100_ref46","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1186\/s12885-019-6150-y","article-title":"Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab","volume":"19","author":"Masuda","year":"2019","journal-title":"BMC Cancer"},{"key":"2024090511564960100_ref47","doi-asserted-by":"crossref","first-page":"475","DOI":"10.21873\/invivo.12281","article-title":"Prognosis of immune-related adverse events in patients with advanced gastric cancer treated with nivolumab or pembrolizumab: a multicenter retrospective analysis","volume":"35","author":"Ando","year":"2021","journal-title":"In Vivo"},{"key":"2024090511564960100_ref48","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1634\/theoncologist.2019-0637","article-title":"Immune-related adverse events and immune checkpoint inhibitor efficacy in patients with gastrointestinal cancer with food and drug administration-approved indications for immunotherapy","volume":"25","author":"Das","year":"2020","journal-title":"Oncologist"},{"key":"2024090511564960100_ref49","doi-asserted-by":"crossref","first-page":"733","DOI":"10.21037\/jgo-23-75","article-title":"Immune-related adverse events as independent prognostic factors for camrelizumab in patients with esophageal squamous cell carcinoma: a retrospective cohort study","volume":"14","author":"Zhao","year":"2023","journal-title":"J Gastrointest Oncol"},{"key":"2024090511564960100_ref50","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1200\/JCO.19.00318","article-title":"Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody","volume":"37","author":"Maher","year":"2019","journal-title":"J Clin Oncol"},{"key":"2024090511564960100_ref51","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1002\/cncr.33780","article-title":"Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors","volume":"127","author":"Foster","year":"2021","journal-title":"Cancer"},{"key":"2024090511564960100_ref52","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102134","article-title":"Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - a systematic review and meta-analysis","volume":"92","author":"Hussaini","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"2024090511564960100_ref53","doi-asserted-by":"crossref","first-page":"175883592098054","DOI":"10.1177\/1758835920980546","article-title":"The association between immune-related adverse events and the prognosis of solid cancer patients treated with immunotherapy: a systematic review and meta-analysis","volume":"12","author":"Xu","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"2024090511564960100_ref54","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.100787","article-title":"Immune-related adverse events as potential surrogates of immune checkpoint inhibitors' efficacy: a systematic review and meta-analysis of randomized studies","volume":"8","author":"Amoroso","year":"2023","journal-title":"ESMO Open"},{"key":"2024090511564960100_ref55","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12916-020-01549-2","article-title":"Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis","volume":"18","author":"Zhou","year":"2020","journal-title":"BMC Med"},{"key":"2024090511564960100_ref56","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1007\/s00262-021-03128-7","article-title":"Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"71","author":"Cheung","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"2024090511564960100_ref57","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jamadermatol.2023.3003","article-title":"Cutaneous adverse events and cancer survival prognosis with immune checkpoint inhibitor treatment: a systematic review and meta-analysis","volume":"159","author":"Du","year":"2023","journal-title":"JAMA Dermatol"},{"key":"2024090511564960100_ref58","doi-asserted-by":"crossref","first-page":"7190","DOI":"10.3748\/wjg.v27.i41.7190","article-title":"Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival","volume":"27","author":"Yamada","year":"2021","journal-title":"World J Gastroenterol"},{"key":"2024090511564960100_ref59","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/07357907.2021.1994586","article-title":"Immune-related liver injury is a poor prognostic factor in patients with nonsmall cell lung cancer treated with immune checkpoint inhibitors","volume":"40","author":"Yamamoto","year":"2022","journal-title":"Cancer Invest"},{"key":"2024090511564960100_ref60","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejca.2021.03.010","article-title":"Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: an overlooked aspect in immunotherapy","volume":"149","author":"Ghisoni","year":"2021","journal-title":"Eur J Cancer"},{"key":"2024090511564960100_ref61","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"2024090511564960100_ref62","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"2024090511564960100_ref63","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ejca.2020.12.012","article-title":"Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors","volume":"145","author":"Skribek","year":"2021","journal-title":"Eur J Cancer"},{"key":"2024090511564960100_ref64","doi-asserted-by":"crossref","first-page":"5993","DOI":"10.1158\/1078-0432.CCR-21-1283","article-title":"Early use of high-dose glucocorticoid for the management of irAE is associated with poorer survival in patients with advanced melanoma treated with anti-PD-1 monotherapy","volume":"27","author":"Bai","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2024090511564960100_ref65","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1001\/jamaoncol.2022.5041","article-title":"Association of immune-related adverse event management with survival in patients with advanced melanoma","volume":"8","author":"Not","year":"2022","journal-title":"JAMA Oncol"},{"key":"2024090511564960100_ref66","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10163744","article-title":"Effect of systemic steroid use for immune-related adverse events in patients with non-small cell lung cancer receiving PD-1 blockade drugs","volume":"10","author":"Mouri","year":"2021","journal-title":"J Clin Med"},{"key":"2024090511564960100_ref67","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26195789","article-title":"Association of systemic steroid treatment and outcome in patients treated with immune checkpoint inhibitors: a real-world analysis","volume":"26","author":"Paderi","year":"2021","journal-title":"Molecules"},{"key":"2024090511564960100_ref68","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol"},{"key":"2024090511564960100_ref69","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.cllc.2022.07.015","article-title":"Immune checkpoint inhibitor rechallenge safety and efficacy in stage IV non-small cell lung cancer patients after immune-related adverse events","volume":"23","author":"Guo","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"2024090511564960100_ref70","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/annonc\/mdx642","article-title":"Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma","volume":"29","author":"Pollack","year":"2018","journal-title":"Ann Oncol"},{"key":"2024090511564960100_ref71","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/S1470-2045(21)00333-8","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis","volume":"22","author":"Zhou","year":"2021","journal-title":"Lancet Oncol"},{"key":"2024090511564960100_ref72","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2024090511564960100_ref73","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/annonc\/mdw558","article-title":"Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature","volume":"28","author":"Spain","year":"2017","journal-title":"Ann Oncol"},{"key":"2024090511564960100_ref74","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11864-020-00768-2","article-title":"Immunotherapy alone or in combination with chemotherapy as first-line treatment of non-small cell lung cancer","volume":"21","author":"Saxena","year":"2020","journal-title":"Curr Treat Options Oncol"},{"key":"2024090511564960100_ref75","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102440","article-title":"Immune checkpoint inhibitor-induced diarrhea and colitis: incidence and management. A systematic review and meta-analysis","volume":"109","author":"Nielsen","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"2024090511564960100_ref76","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1001\/jamaoncol.2017.4526","article-title":"EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer","volume":"4","author":"Oshima","year":"2018","journal-title":"JAMA Oncol"},{"key":"2024090511564960100_ref77","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1089\/thy.2023.0542","article-title":"The combined effect of immune checkpoint inhibitors and tyrosine kinase inhibitors on thyroid function","volume":"34","author":"Tsai","year":"2024","journal-title":"Thyroid"},{"key":"2024090511564960100_ref78","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1186\/s12885-020-07142-3","article-title":"Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody","volume":"20","author":"Matsuoka","year":"2020","journal-title":"BMC Cancer"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/9\/949\/59016334\/hyae067.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/9\/949\/59016334\/hyae067.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T19:02:37Z","timestamp":1725562957000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/54\/9\/949\/7676525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,20]]},"references-count":78,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,5,20]]},"published-print":{"date-parts":[[2024,9,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyae067","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,5,20]]}}}